Ascelia's pivotal SPARKLE study will now be completed with 80 patients (earlier up to 200) and we can expect completion by February-March (earlier end 2022) with top-line read out in mid-2023. This is mainly positive as we welcome the clarity and especially as the main reason for the patient reduction is that a new review demonstrates a "strong and statistically significant effect".